Scoop: Forma axes discovery biology team as part of a broader reorganization
We just got tipped off about layoffs at Forma Therapeutics yesterday. Staffers tell us that 25 people in discovery biology got the ax, with execs attributing the cuts to issues involving their pact with Celgene. CEO Steve Tregay confirmed that there have been cuts, adding that they are part of a broader reorganization that is claiming 61 jobs at the company.
But Tregay declined to say anything about the Celgene relationship, which is a cornerstone of the Watertown, MA-based company.
According to Steve Tregay:
Basic subscription required
Unlock this story instantly and join 57,800+ biopharma pros reading Endpoints daily — and it's free.